Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
510
Trial Sponsor
Clinical Trial Start Date
2007
0Primary Completion Date
2009
0Study Completion Date
2009
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Interventional Trial Phase
Phase 30
Official Name
A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency0
Last Updated
September 1, 2011
0Allocation Type
Non-Randomized0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)0
Study summary
The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
